Newsfile Corp
13 Sept 2026, 07:15 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
The FDA AdCom panel concluded in a 9-3 vote that available evidence does not support the efficacy of Deramiocel for treating DMD-associated cardiomyopathy. — A negative efficacy conclusion from an FDA advisory panel is a primary catalyst for drug failure and severe valuation loss for biotech companies.
-0.90FDA briefing documents stated that the benefit-risk assessment for Deramiocel appears unfavorable due to a lack of evidence of effectiveness. — Direct negative feedback from the regulatory body significantly reduces the probability of BLA approval.
-0.80A federal securities class action lawsuit alleges Capricor made misleading statements by changing clinical data analysis plans without FDA agreement. — Litigation creates additional financial liability and suggests potential governance or transparency failures within the company.
-0.40Which stocks this story touches
Continue reading
5 related stories
Search tags
The company is facing a federal securities class action lawsuit and significant stock price drops following negative FDA and AdCom findings on its lead drug candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
2h ago
